Literature DB >> 10847523

The variable presentation and natural history of Langerhans cell histiocytosis.

J A Buckwalter1, E Brandser, R A Robinson.   

Abstract

Langerhans cell histiocytosis is not a well defined or predictable disease. Instead, it is a spectrum of disorders of unknown etiology that vary widely in presentation and natural history, but have in common the proliferation of histiocytic cells and infiltration of these cells into normal tissues. Although the lesions of Langerhans cell histiocytosis consist primarily of histiocytes, eosinophils are a prominent feature in some lesions. Lesions may develop in any tissue, but bone, skin and lymph nodes are the most commonly affected, and more than 75% of patients have skeletal lesions. Bone lesions caused by Langerhans cell histiocytosis vary from focal sharply defined areas of bone lysis to diffuse osteopenia and can resemble lesions caused by a wide variety of metabolic, infectious and neoplastic diseases. The natural history varies from a benign disorder that resolves spontaneously to a progressive fatal disease. In general, the younger the individual at the time of onset of the disease, the poorer the prognosis and the more extensive the disease. Treatment may include surgery, chemotherapy and radiation therapy, depending on the extent and severity of the disease.

Entities:  

Mesh:

Year:  1999        PMID: 10847523      PMCID: PMC1888619     

Source DB:  PubMed          Journal:  Iowa Orthop J        ISSN: 1541-5457


  17 in total

Review 1.  Langerhans' cell histiocytosis pathobiology and pathogenesis.

Authors:  B E Favara
Journal:  Semin Oncol       Date:  1991-02       Impact factor: 4.929

2.  Langerhans cell histiocytosis: unusual skeletal manifestations observed in thirty-four cases.

Authors:  B W Hindman; R D Thomas; L W Young; L Yu
Journal:  Skeletal Radiol       Date:  1998-04       Impact factor: 2.199

3.  Langerhans' cell histiocytosis (histiocytosis X) of bone. A clinicopathologic analysis of 263 pediatric and adult cases.

Authors:  S E Kilpatrick; D E Wenger; G S Gilchrist; T C Shives; P C Wollan; K K Unni
Journal:  Cancer       Date:  1995-12-15       Impact factor: 6.860

Review 4.  Langerhans cell histiocytosis.

Authors:  R M Egeler; G J D'Angio
Journal:  J Pediatr       Date:  1995-07       Impact factor: 4.406

5.  Direct injection of methylprednisolone sodium succinate in the treatment of solitary eosinophilic granuloma of bone: a report of 9 cases.

Authors:  M Cohen; J Zornoza; A Cangir; J A Murray; S Wallace
Journal:  Radiology       Date:  1980-08       Impact factor: 11.105

6.  Langerhans cell histiocytosis: presentation and evolution of radiologic findings with clinical correlation.

Authors:  J S Meyer; M P Harty; S Mahboubi; S Heyman; R A Zimmerman; R B Womer; J P Dormans; G J D'Angio
Journal:  Radiographics       Date:  1995-09       Impact factor: 5.333

7.  Treatment of Langerhans-cell histiocytosis in children. Experience at the Children's Hospital of Nancy.

Authors:  S Sessa; D Sommelet; P Lascombes; J Prévot
Journal:  J Bone Joint Surg Am       Date:  1994-10       Impact factor: 5.284

8.  Direct cortisone injection in eosinophilic granuloma of bone: a preliminary report on 11 patients.

Authors:  R Capanna; D S Springfield; P Ruggieri; R Biagini; P Picci; G Bacci; A Giunti; E G Lorenzi; M Campanacci
Journal:  J Pediatr Orthop       Date:  1985 May-Jun       Impact factor: 2.324

9.  Langerhans cell (eosinophilic) granulomatosis. A clinicopathologic study encompassing 50 years.

Authors:  P H Lieberman; C R Jones; R M Steinman; R A Erlandson; J Smith; T Gee; A Huvos; P Garin-Chesa; D A Filippa; C Urmacher; M D Gangi; M Sperber
Journal:  Am J Surg Pathol       Date:  1996-05       Impact factor: 6.394

Review 10.  Langerhans cell histiocytosis in children under 2 years of age.

Authors:  R Rivera-Luna; N Alter-Molchadsky; R Cardenas-Cardos; G Martínez-Guerra
Journal:  Med Pediatr Oncol       Date:  1996-05
View more
  1 in total

1.  Atypical presentation of isolated orbital Langerhans cell histiocytosis.

Authors:  Nikisha Q Richards; Matthew Young; Kasey Pierson; John Le; Yuan Rong
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.